This brand name is authorized in France, Poland
The drug MIBITEC contains one active pharmaceutical ingredient (API):
|
1
Technetium ⁹⁹ᵐTc sestamibi
UNII N6OU7HJ70P - TETRAKIS(2-METHOXYISOBUTYLISOCYANIDE)COPPER(I) TETRAFLUOROBORATE
|
|
Technetium 99mTc sestamibi is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands, hence the name sesta (6) MIBI. Following intravenous injection of the drug, Technetium 99mTc sestamibi is taken up by the myocardium, parathyroid, and/or breast tissue. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| V09GA01 | Technetium (99mTc) sestamibi | V Various → V09 Diagnostic radiopharmaceuticals → V09G Cardiovascular system → V09GA Technetium (99mTc) compounds |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: FR | Base de données publique des médicaments | Identifier(s): 69987156 |
| Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100279915 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
